IMA-301
/ Immatics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 03, 2020
Immatics Announces Second Quarter 2020 Financial Results and Business Update
(GlobeNewswire)
- "IMA301 – A preclinical data update is expected to be presented in Q4 2020. IND-enabling studies are ongoing and Immatics expects to submit the IND in 2022....Immatics intends to report updated clinical trial results for its multi-target cell therapy pilot clinical trial, IMA101-101, in Q4 2020."
IND • P1 data • Preclinical • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1